Sylvie Ryckebusch
Corporate Officer/Principal en BIOINVENT INTERNATIONAL AB .
Fortuna: 42 331 $ al 30/04/2024
Cargos activos de Sylvie Ryckebusch
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| BIOINVENT INTERNATIONAL AB | Corporate Officer/Principal | 09/06/2022 | - |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director/Miembro de la Junta | - | - |
Historial de carrera de Sylvie Ryckebusch
Formación de Sylvie Ryckebusch.
| California Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Francia | 2 |
| Suecia | 2 |
Operativa
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Empresas privadas | 1 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
- Bolsa de valores
- Insiders
- Sylvie Ryckebusch
- Experiencia
